Idanis Berrios Morales, MD
Neurology · Worcester, MANPI 1871880906
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (38.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Reporting peaked in 2019 at $1,273 and has fallen 67.4% since, to $415 in 2022.
Across 6 payments — averaging $457.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$1K
- Hoffmann-la Roche Limited$1K
Across 169 payments — averaging $2272.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- TG Therapeutics, Inc.$308K
- EMD Serono, Inc.$70K
- Sanofi$6K
- Ares Trading SA$850
- Novartis$15
What the payments were for
- Speaking & faculty fees$41515%
- Travel & lodging$94234%
- Food & beverage$33112%
- Education$1,05438%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 3 | $1,470 |
| Hoffmann-la Roche Limited | 3 | $1,273 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$1,273
How this compares
$2,743 in reported general payments places this provider in the 65th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 97 | $931,927 |
| TecfideraDimethyl Fumarate | 20 | $173,204 |
| CopaxoneGlatiramer Acetate | 21 | $127,772 |
| Dalfampridine ErDalfampridine | 41 | $27,492 |
| Baclofen | 202 | $6,309 |
| Modafinil | 56 | $3,815 |
| ValacyclovirValacyclovir Hcl | 28 | $3,785 |
| Dimethyl Fumarate | 17 | $3,764 |
| Teriflunomide | 20 | $2,127 |
| Gabapentin | 155 | $2,043 |
| Sumatriptan Succinate | 17 | $1,604 |
| Pregabalin | 53 | $1,302 |
| AmantadineAmantadine Hcl | 26 | $960 |
| Tizanidine Hcl | 37 | $568 |
| Dantrolene Sodium | 11 | $473 |
Paid to pharmacies, not to this prescriber.
Other neurology in Worcester
- Herbert MarkleyWorcester$183K
- Carolina IoneteWorcester$144K
- Christopher WrightBoston$2.5M
- Shivang JoshiWestborough$1.2M
- Egilius SpieringsWellesley Hills$680K
- Thomas ScammellBoston$617K
- Salvatore NapoliFoxboro$613K
- Alfred SandrockBoston$490K
- Joshua KatzWellesley$462K
- Guy BuckleBrookline$450K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.